中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

对阿德福韦酯自然变异耐药与抗病毒后耐药的慢性乙型肝炎患者血清HBV P基因序列比较

汪莉萍 韩方正 李春杨 闫梅 张言超 颜学兵

引用本文:
Citation:

对阿德福韦酯自然变异耐药与抗病毒后耐药的慢性乙型肝炎患者血清HBV P基因序列比较

基金项目: 

江苏省卫生厅2011年科教兴卫工程医学重点人才支持计划[苏卫科教(2011)15号]; 

详细信息
  • 中图分类号: R512.62

Evaluation of adefovir primary resistance and adefovir repulsive mutations of the HBV DNA P gene in chronic hepatitis B patients

Research funding: 

 

  • 摘要: 目的通过对慢性乙型肝炎(CHB)患者外周血乙型肝炎病毒(HBV)聚合酶RT区序列分析,观察对阿德福韦酯(ADV)自然变异耐药及继发耐药的异同。方法 PCR产物直接测序法检测78例对ADV耐药患者外周血HBV RT区基因序列。其中曾用ADV治疗患者30例(治疗组),未抗病毒治疗48例(未治疗组),并对两组ADV相关耐药变异位点发生频数进行比较。结果未治疗组ADV耐药的主要变异类型为rtA181V/T 10例(20.8%),rtN/H238T/D/S 10例(20.8%)和rtV214A变异13例(27.1%);而治疗组发生的ADV耐药变异主要为rtA181V/T 16例(53.3%),没有发现rtN/H238T/D/S变异,仅发现1例rtV214A变异。结论CHB患者中存在相当严重的ADV自然变异耐药变异,主要变异类型为rtN/H238T/D/S及rtV214A,而抗病毒治疗后该变异位点发生频数反而相对减少。rtA181V/T变异既可以为自然变异也可以由ADV抗病毒治疗而诱发。

     

  • [1]Locarnini S, Qi X, Arterburn S, et al.Incidence and predic-tors of emergence of HBV mutations associated with ADV re-sistance during 4 years of adefovir therapy for patients withchronic HBV[J].Hepatology, 2006, 41:A36.
    [2]杨海红, 曾文铤, 卫建筠.乙型肝炎病毒基因型与拉米夫定疗效关系研究[J].热带医学杂志, 2006, 6 (2) :215-216.
    [3]Angus P, Vaughan R, Xiong S, et al.Resistance to adefovir-dipivoxil therapy associated with the selection of a novel mu-tation in the HBV polymerase[J].Gastroenterology, 2003, 125 (2) :292.
    [4]Qi X, Snow A, Thibault V, et al.Longterm incidence of adefovirdipivoxil resistance in chronic hepatitis B patients after 144weeks of therapy[J].Hepatology, 2004, 40 (suppl1) :57.
    [5]Perrillo R, Hann HW, Mutimer D, et al.Adefovir dipivoxil addedto ongoing lamivudine in chronic hepatitis B with YMDD mutanthepatitis B virus[J].Gastroenterology, 2004, 126 (1) :81.
    [6]Barcena R, Del Campo S, Moraleda G, et al.Study on theefficacy and safety of adefovir dipivoxil treatment in post livertransplant patients with hepatitis B virus infection and lamivu-dine resistant hepatitis B virus[J].Transplant Proc, 2005, 37 (9) :3960-3962.
    [7] 汪莉萍, 韩方正, 李春杨, 等.慢性乙型肝炎患者抗病毒治疗前HBV P区基因序列测定的意义[J].中华临床感染病杂志, 2011, 4 (5) :298-300.
    [8]Kobayashi S, Ide T, Sata M.Detection of YMDD motif muta-tions in some lamivudine-untreated asymptomatic hepatitisB virus carriers[J].Hepatology, 2001, 34 (4) :584-586.
    [9]Heo J, Cho M, Kim HH, et al.Detection of YMDD motifmutants by oligonucleotide chips in lamivudine untreated pa-tients with chronic hepatitis B virus infection[J].J KoreanMed Sci, 2004, 19 (4) :541-546.
    [10]孙海平, 王磊, 杨芳.核苷 (酸) 类似物相关H BV P基因耐药变异焦磷酸测序[J].山东大学医学报:医学版, 2010, 48 (5) :85-88.
    [11]Mirandola S, Campagnolo D, Bortoletto G, et al.Large-scalesurvey of naturally occurring HBV polymerase mutations associat-ed with anti-HBV drug resistance in untreated patients with chro-nic hepatitis B[J].J Viral Hepat, 2011, 18 (7) :e212-216.
    [12]Ismail AM, Samuel P, Eapen CE, et al.Antiviral resistancemutations and genotype-associated amino acid substitu-tions in treatment-nave hepatitis B virus-infected individu-als from the Indian subcontinent[J].Intervirology, 2012, 55 (1) :36-44.
    [13]Yeh CT, Chien RN, Chu CM, et al.Clearance of the originalhepatitis B virus YMDD motif mutants with emergence of dis-tinct lamivudine-resistantmutants during prolonged lamivudinetherapy[J].Hepatology, 2000, 31 (6) :1318-1326.
    [14]Bartholomcusz A, Locarnini SA.Antiviral drug resistance:clinical consequences and molecular aspects[J].SeminLiver Dis, 2006, 26 (2) :162-170.
  • 加载中
计量
  • 文章访问数:  2851
  • HTML全文浏览量:  19
  • PDF下载量:  690
  • 被引次数: 0
出版历程
  • 出版日期:  2012-08-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回